Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Opus Genetics, Inc.RNN · Entity 5892 | Director · Chief Executive Officer | February 28, 2018 | March 02, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Opus Genetics, Inc.
Report date February 28, 2018 · Filed March 02, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,250 |
Reported balance
After 2018-02-28 transaction · row 1
1 source rowRow 1 · 2018-02-28 · Exercise / conversion · Acquired 6,250 · Balance 22,250 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 18,750 |
Reported balance
After 2018-02-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-02-28 · Exercise / conversion · Acquired 6,250 · Balance 18,750 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. F2: On January 20, 2017, the reporting person was granted 25,000 RSUs, of which 6,250 vested on February 28, 2018. The remaining RSUs will vest in three equal annual installments on the last business day in February, beginning February 28, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock.
F2: On January 20, 2017, the reporting person was granted 25,000 RSUs, of which 6,250 vested on February 28, 2018. The remaining RSUs will vest in three equal annual installments on the last business day in February, beginning February 28, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2018 Filed Mar 2, 2018 16:26 UTC | Opus Genetics, Inc. RNN · Entity 5892 | Exercise / conversionRestricted Stock Units · Derivative | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-011646 · form4.xml · derivative · entry 2 Suzdak Peter David · CIK 0001296629 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 6,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: On January 20, 2017, the reporting person was granted 25,000 RSUs, of which 6,250 vested on February 28, 2018. The remaining RSUs will vest in three equal annual installments on the last business day in February, beginning February 28, 2019. F2 · derivative.expiration_date: On January 20, 2017, the reporting person was granted 25,000 RSUs, of which 6,250 vested on February 28, 2018. The remaining RSUs will vest in three equal annual installments on the last business day in February, beginning February 28, 2019. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 16:26 UTC | Opus Genetics, Inc. RNN · Entity 5892 | Exercise / conversionCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-011646 · form4.xml · nonDerivative · entry 1 Suzdak Peter David · CIK 0001296629 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2018 Filed Jan 30, 2018 16:39 UTC | Opus Genetics, Inc. RNN · Entity 5892 | GrantStock Option (right to buy) · Derivative | 112,271 | $0.00 Strike: $2.29 | $0.00 |
DisclosureSEC source: 0001140361-18-003900 · form4.xml · derivative · entry 1 Suzdak Peter David · CIK 0001296629 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,271 Underlying: Common Stock · 112,271 shares Expires 2028-01-26 F1 · derivative.exercise_date: One quarter of the option vests and becomes exercisable on January 26, 2019, and, thereafter, 1/36th of the remaining option vests in equal installments on the first business day of each month until fully vested. Read SEC document |
| August 16, 2017 Filed Aug 16, 2017 16:05 UTC | Opus Genetics, Inc. RNN · Entity 5892 | GrantCommon Stock | 10,000 | $1.99 | $19,872.00 |
DisclosureSEC source: 0001140361-17-032420 · form4.xml · nonDerivative · entry 1 Suzdak Peter David · CIK 0001296629 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 F1 · price: The price of $1.9872 per share represents a weighted average of purchase prices ranging from $1.96 to $2.01 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| January 20, 2017 Filed Jan 24, 2017 17:50 UTC | Opus Genetics, Inc. RNN · Entity 5892 | GrantRestricted Stock Units · Derivative | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-002736 · form4.xml · derivative · entry 2 Suzdak Peter David · CIK 0001296629 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments on the last business day in February, beginning February 28, 2018. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments on the last business day in February, beginning February 28, 2018. Read SEC document |
| January 20, 2017 Filed Jan 24, 2017 17:50 UTC | Opus Genetics, Inc. RNN · Entity 5892 | GrantStock Option (right to buy) · Derivative | 1,175,000 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0001140361-17-002736 · form4.xml · derivative · entry 1 Suzdak Peter David · CIK 0001296629 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,175,000 Underlying: Common Stock · 1,175,000 shares Expires 2027-01-20 F1 · derivative.exercise_date: One quarter of the option vests and becomes exercisable on January 20, 2018, and, thereafter, 1/36th of the remaining option vests in equal installments on the first business day of each month until fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.